TRUMY - Terumo Deserves A Closer Look Ahead Of New Revenue And Margin Opportunities
- Terumo is set to benefit from a resumption of elective medical procedures in developed markets, but also new product introductions in cardiology, neurology, and diabetes.
- Winning CSL's plasma collection business gives Terumo a new growth driver with double-digit market growth and attractive margins.
- The entire med-tech sector has meaningfully re-rated over the past decade, but Terumo still offers a reasonable return potential today.
For further details see:
Terumo Deserves A Closer Look Ahead Of New Revenue And Margin Opportunities